Ashvattha Therapeutics, Inc.
Harnessing the power of hydroxyl dendrimers to create a new class of disease cell-targeted precision medicine
24 employees · est. 2015 · Redwood City, United States
Ashvattha Therapeutics, Inc. is the older company (2015 vs 2017).
Side-by-Side Comparison
| Metric | Ashvattha Therapeutics, Inc. | ProteinQure |
|---|---|---|
| Founded | ||
| Founded | 2015 older | 2017 |
| Headquarters | ||
| Headquarters | Redwood City, United States | Toronto, Canada |
| Employees | ||
| Employees | 24 | 32 |
| Industry | ||
| Industry | Biotechnology, Health Care, Health and Wellness | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series B | Series A |
| Total Funding | ||
| Total Funding | $148.04M | $18.12M |
| Funding Rounds | ||
| Funding Rounds | 5 | 6 |
| Services | ||
| Services | Development of precision nanomedicines, Treatment of ophthalmology, neurology, and inflammatory diseases, Conducting clinical trials and aligning with regulatory pathways | Development of AI-designed peptide-drug conjugates, Precision drug delivery solutions, Proprietary computational platform (ProteinStudio) for peptide design, Clinical trials for peptide-based therapeutics, Research and development in oncology solutions |
| Target Customers | ||
| Target Customers | Patients with ophthalmological, neurological, and inflammatory conditions, Healthcare providers and clinics focused on innovative treatments, Researchers and partners in biopharmaceutical development | Pharmaceutical companies, Biotech researchers, Clinical oncology specialists, Medical research institutions, Patients with advanced solid tumors |
| Taxonomy | ||
| Taxonomy | Hydroxyl Dendrimers, Precision Medicine, Drug Delivery Platform, Neurology Therapeutics, Ophthalmology Therapeutics, Hyperinflammatory Diseases, Neuro-oncology, Targeted Drug Delivery, Small Molecule Drugs, Therapeutic Development, Disease Cell Targeting, Selective Drug Delivery, Off-target Toxicity Reduction, Johns Hopkins University License, Innovative Drug Research | AI Platform For Drug Design, Peptide Drug Design, Extracellular Targets, TOP1-resistant Breast Cancer, Phase I Clinical Trials, Pharmaceutical Collaborations, Proprietary Physics-based Methods, Chemical Space Exploration, Scaffold Diversity, Non-canonical Building Blocks, Tissue-specific Payload Delivery, SiRNA Delivery, Central Nervous System Therapies |
| Website | ||
| Website | avttx.com | proteinqure.com |
About Ashvattha Therapeutics, Inc.
Ashvattha Therapeutics, Inc., founded in 2015, is a pioneering force in the biotechnology and pharmaceutical sectors. Operating from its headquarters in the United States, the company is dedicated to transforming precision medicine through its proprietary hydroxyl dendrimer (HD) platform, exclusivel...
About ProteinQure
ProteinQure, founded in 2017 and headquartered in Canada, is at the forefront of biotechnology. Armed with the slogan "dare to deliver," the company is pioneering an AI platform designed for peptide drug design, particularly targeting extracellular targets. Their flagship program, PQ203, is current...
We will tell you when either one moves
BounceWatch watches Ashvattha Therapeutics, Inc. and ProteinQure for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Ashvattha Therapeutics... and ProteinQure — by email.
Frequently Asked Questions
Compare Ashvattha Therapeutics, Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Ashvattha Therapeutics, Inc. on 30 Apr 2026, and ProteinQure on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
